This spring and summer, the Sabin Vaccine Institute (Sabin) has been amplifying the voices of parents who immunize through the Give Your Kids A Shot campaign on Twitter

Sabin Vaccine Institute Receives $20.5 Million from BARDA with Potential of up to $128 Million to Develop Ebola Sudan and Marburg Vaccines

WASHINGTON, D.C. – The Sabin Vaccine Institute (Sabin) today announced a funding award of $20.5 million with options for an additional $107.5 million from the Biomedical Advanced Research and Development Authority (BARDA) within the U.S. Department of Health and Human Services.

Vaccines save millions of lives every year, but recent outbreaks demonstrate the tenuous nature of this achievement. The Sabin Vaccine Institute (Sabin) is launching a research program to better understand the factors leading some to accept vaccination and others to delay or refuse it.

GSK Grants Exclusive Technology License For Clinical-Stage Ebola Vaccines To Sabin Vaccine Institute

LONDON / WASHINGTON, D.C. – GSK and the Sabin Vaccine Institute (Sabin) today announced exclusive agreements for Sabin to advance the development of the prophylactic candidate vaccines against the deadly Ebola Zaire, Ebola Sudan and the closely related, but lesser known, Marburg virus.

When Ebola virus disease swept through Guinea, Liberia and Sierra Leone in 2014, the world saw firsthand the shortcomings of the global response.

Global Communities had spent four years building access to safe sanitation in Liberia when the Ebola epidemic struck and revealed a surprising impact.

As experimental Ebola vaccines start to head toward large clinical trials in Africa, a report released by Wellcome Trust and the Center for Infectious

Pages